Adma Biologics Implements AI Program for Improved Production

By Tamara Parker • Wednesday, February 21 12:04 • Permanent Link

Adma Biologics, Inc. (NASDAQ: ADMA) has announced the successful implementation of its innovative artificial intelligence (AI) program, named ADMALYTICS. The program combines generative AI and machine learning to optimize production processes.

Adma Biologics utilized ADMALYTICS for the first time to automate and improve efficiency in commercial production plasma pooling, specifically for its first batch of Asceniv™. The company anticipates that broader implementation of ADMALYTICS will bring efficiencies across the organization.

Adam Grossman, President and CEO of Adma, highlighted the significance of this achievement, stating, "We're proud to announce the successful development and implementation of our innovative ADMALYTICS AI program. This achievement aligns seamlessly with our overarching mission to continuously innovate our production processes for specialty biologics, while also building on our reputation as a thought leader within the commercial specialty biologics markets for the patients our therapies serve."

Grossman also emphasized the potential impact of ADMALYTICS, stating, "The robust ADMALYTICS AI program is designed to optimize and streamline our intricate production processes, delivering significant efficiencies throughout the organization. In the complex landscape of specialty biologics production, maintaining uninterrupted operations is paramount, and we believe that ADMALYTICS will further bolster our commitment to ensuring continuity of patient care."

Adma Biologics, Inc. is dedicated to manufacturing, marketing, and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The company currently manufactures and markets three FDA-approved plasma-derived biologics.

Following the announcement, the company's shares have moved 1.9%, and are now trading at a price of $5.25.

The company's full 8-K submission is available here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.